TG Therapeutics, Inc. (TGTX)
- Previous Close
17.12 - Open
17.23 - Bid 16.91 x 400
- Ask 16.94 x 800
- Day's Range
16.83 - 17.34 - 52 Week Range
6.46 - 33.58 - Volume
2,677,835 - Avg. Volume
3,775,830 - Market Cap (intraday)
2.615B - Beta (5Y Monthly) 2.33
- PE Ratio (TTM)
56.40 - EPS (TTM)
0.30 - Earnings Date Jul 30, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
32.29
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
www.tgtherapeutics.comRecent News: TGTX
Performance Overview: TGTX
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TGTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TGTX
Valuation Measures
Market Cap
2.61B
Enterprise Value
2.52B
Trailing P/E
56.40
Forward P/E
70.42
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.77
Price/Book (mrq)
16.33
Enterprise Value/Revenue
8.70
Enterprise Value/EBITDA
46.56
Financial Highlights
Profitability and Income Statement
Profit Margin
14.24%
Return on Assets (ttm)
10.59%
Return on Equity (ttm)
43.93%
Revenue (ttm)
289.33M
Net Income Avi to Common (ttm)
41.2M
Diluted EPS (ttm)
0.30
Balance Sheet and Cash Flow
Total Cash (mrq)
209.78M
Total Debt/Equity (mrq)
69.95%
Levered Free Cash Flow (ttm)
-2.9M
Research Analysis: TGTX
Company Insights: TGTX
TGTX does not have Company Insights